Clearside Biomedical (CLSDQ) Stock Statistics & Valuation Metrics

Clearside Biomedical has a market cap or net worth of $1.31M. The enterprise value is $55.39M.

Clearside Biomedical has 5,233,981 shares outstanding. The number of shares has decreased by -2.65% in one year.

Clearside Biomedical’s return on equity (ROE) is 0.88 and return on invested capital (ROIC) is -139.48%.

The current PE Ratio of Clearside Biomedical is ―. Clearside Biomedical’s PEG ratio is 0.18.

In the last 12 months, Clearside Biomedical had revenue of 1.66M and earned -34.35M in profits. Earnings per share was -6.98.

In the last 12 months, operating cash flow was -21.29M and capital expenditures -453.00K, giving a free cash flow of -21.74M billion.

Clearside Biomedical pays an annual dividend of ―, resulting in a dividend yield of ―

Clearside Biomedical upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Clearside Biomedical as a current ratio of 4.44, with Debt / Equity ratio of -114.20%

In the past 12 months, Clearside Biomedical has paid 0.00 in taxes.

Clearside Biomedical EV to EBITDA ratio is -4.21, with an EV/FCF ratio of -3.99.

Clearside Biomedical has $6.80M in cash and marketable securities with $61.61M in debt, giving a net cash position of -$54.81M billion.

Gross margin is 89.02%, with operating margin of -1735.70%, and net profit margin of -2064.42%.

The average price target for Clearside Biomedical is ―, which is 11.43% higher than the current price. The consensus rating is ―